← Russell 3000 cross-section

REGN REGENERON PHARMACEUTICALS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Healthcare

Scale

Market cap
$85.8bn
Revenue TTM
$15.5bn
Net income TTM
$4.3bn
Free cash flow
$3.8bn
Composite score
63.5
Sector rank
#148

Valuation

P / E
19.8
EV / EBITDA
18.3
EV / sales
5.1
FCF yield
4.38%
Earnings yield vs 10-yr
0.31pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
27.9%
EBITDA margin
28.1%
ROE
13.7%
ROIC
14.9%
Revenue growth
9.3%

Insider activity, last 90 days

Net open-market
$-1.09m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We and Sanofi equally share profits from sales within the United States, and share profits outside the United States on a sliding scale based on sales starting at 65% (Sanofi)/35% (us) and ending at 55% (Sanofi)/45% (us). We will lead development and commercialization, and Parabilis will be eligible to receive milestone payments for development, regulatory and commercial milestones, as well as tiered royalties up to low double-digits on sales. …REGENERON PHARMACEUTICALS, INC., 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →